Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Shares Outstanding (Diluted Average) (2020 - 2024)

Solid Biosciences' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $40.2 million for Q3 2024.

  • For Q3 2024, Shares Outstanding (Diluted Average) rose 100.31% year-over-year to $40.2 million; the TTM value through Sep 2024 reached $40.2 million, up 100.31%, while the annual FY2023 figure was $19.9 million, 133.6% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2024 was $40.2 million at Solid Biosciences, up from $39.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $112.3 million in Q2 2021 and bottomed at $3.5 million in Q4 2020.
  • The 5-year median for Shares Outstanding (Diluted Average) is $19.6 million (2023), against an average of $23.9 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) crashed 93.3% in 2022 before it soared 166.3% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $3.5 million in 2020, then surged by 105.58% to $7.1 million in 2021, then grew by 19.58% to $8.5 million in 2022, then surged by 133.6% to $19.9 million in 2023, then soared by 102.08% to $40.2 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Shares Outstanding (Diluted Average) are $40.2 million (Q3 2024), $39.5 million (Q2 2024), and $38.2 million (Q1 2024).